TNFSF10 and cancer: Therefore, alternative pathways of TRAIL resistance are likely present in non-gastrointestinal cancers, in cancers other than adenocarcinoma, or in different organs.26 Despite this limitation, we did evaluate the phenotype in additional colon, gastric and pancreatic cancer cell lines and observed similar results in apoptosis and DR expression.